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Genetic engineering in mice has provided much information
about gene function in renal health and disease. This
knowledge has largely come from conventional transgenic
approaches. Recently, methods have been developed to
control the cell type, timing and reversibility of target gene
expression. Advances in identifying promoters conferring
renal cell-specific gene regulation in vivo have greatly
facilitated interpretation of gene targeting studies.
Site-specific recombinases have permitted cell-specific
knockout of genes; Cre is the preeminent recombinase, but
recent progress with other recombinases, include Flp and
UC31, will likely increase the usefulness of this class of
enzymes. Temporally regulated gene expression, particularly
using doxycycline- and tamoxifen-inducible systems, holds
great promise for avoiding developmental effects of gene
mutations as well as facilitating comparison of the same
animal’s phenotype before and after gene modification. RNA
interference is undergoing tremendous growth and has great
potential for achieving gene knockdown quickly and
reversibly. To date, however, the utility of these systems in
modifying renal function in transgenic mice remains
unproven. Finally, new gene targeting tools are in
development that may substantially simplify generation of
transgenic animals. This review discusses the state-of-the-art
in gene targeting in the kidney, reviewing function,
indications and limitations of the molecular biologic tools.
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Genetically engineered mice have proven to be highly useful
tools for assessing the role of specific gene products in renal
health and disease. The original approaches involved (1) gene
overexpression, largely through transgene injection into
oocytes and (2) traditional gene knockout using embryonic
stem (ES) cells. Although these methods yielded much
information, they have significant limitations. Oocyte injec-
tion causes wide variations in the amount and location (cell
type) of transgene expression. Conventional gene targeting
greatly improved the ability to assess gene function. This
involves homologous recombination at the target gene locus
in ES cells, ultimately leading to gene inactivation and/or
inserted transgene expression in mice derived from these
cells. However, two major problems arise from this strategy.
First, because the mutation is present throughout mouse
ontogeny, it is not uncommon to have undesired develop-
mental effects occur, some of which are embryonic or
perinatal lethal. Second, all cells in the body are affected by
the mutation. This can lead to complex phenotypes that
confound interpretation. Even when the anticipated pheno-
type is obtained, it can be problematic to ascribe this to gene
dysfunction or overexpression in a particular tissue. To
circumvent these problems, conditional gene targeting
strategies were devised that allow control of the timing and
location (cell type(s)) of gene expression and/or inactivation.
This review will focus on these advances in gene targeting and
how they have been applied in renal-related research. In
addition, new strategies for modifying gene expression,
including use of RNA interference, will be discussed.
RECOMBINASES AND CELL-SPECIFIC GENE EXPRESSION
Overview
Site-specific recombinases (SSRs) catalyze recombination
between two homologous DNA sequences (see review Feil
20071). In general, the required components are (1) two
identical DNA sequences (often only 30–40 bp) at which
recombination occurs and (2) an SSR that binds these DNA
sites, cleaves them, and anneals them (Figure 1). Depending
upon how the system is structured, excision, inversion,
integration, or exchange of target DNA can occur. Inversion
occurs when the SSR-recognition sites are in the opposite
orientation, whereas excision occurs when they are in the
same orientation. If the SSR-recognition sites are on separate
DNA molecules, integration or strand exchange can occur.
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The reaction requires no cofactors and relatively few SSR
molecules, making these systems potentially highly adaptable
to, and efficient in, transgenic animals.
The fundamental strategy most widely employed for SSR-
mediated gene modification involves generation of mice,
typically using ES cell technology, with insertion of two SSR-
recognition sites in the same orientation that flank a region
essential for protein activity in a target allele. These mice are
bred with a second mouse line expressing the SSR under
control of a promoter. Offspring have SSR-mediated deletion
of the SSR-recognition site-flanked target allele DNA within
cells expressing the SSR. In this way, the selected promoter
determines which cells undergo target allele disruption.
There are two known families of SSRs based on distinct
catalytic amino acids, the tyrosine (l-integrase) and serine
(resolvase) recombinases.1 The most commonly used SSR
systems for genetic studies on animals, Cre/lox and Flp/FRT,
are based on tryrosine recombinases. Serine recombinase
systems, such as FC31/att and b-recombinase/six, are
effective in cultured cells and may be useful for studies on
mice; however, these SSRs require a certain degree of DNA
supercoiling that may not be present in eukaryotic cells.1
The Cre/lox system
The Cre/lox system, originally described in bacteriophage
P1,2 is the recombinase system used most widely to achieve
cell-specific gene targeting in mice. The two following
components are involved: (1) a 34-bp DNA sequence
containing two 13-bp inverted repeats and an asymmetric
8-bp spacer region termed loxP that targets recombination;
and (2) a 343-amino-acid monomeric protein termed Cre
recombinase that mediates the recombination event. As
illustrated in Figure 1, any DNA sequence flanked by two loxP
sites in the same orientation will be excised. A major
advantage of the Cre/loxP system lies in its relative simplicity.
First, no cofactors are required for Cre activity. This is a
result of the Cre/loxP complex providing the necessary energy
through formation of phosphotyrosine intermediates at the
point of strand exchange. Second, loxP target sites are small
and easily synthesized. Third, there are no apparent external
energy requirements. Fourth, Cre is a very stable protein.
Finally, it is possible to generate DNA constructs with a wide
variety of promoters driving Cre expression.
The power and versatility of the Cre/loxP system is largely
a function of promoter activity. Several promoters have been
used to achieve Cre expression in a cell-specific manner in
the kidney (Table 1). A few of these Cre transgenic mice have
proven successful in yielding a mutant phenotype upon
target-gene excision, evidence that active Cre is expressed in a
sufficient number of cells to exert a detectable biologic effect.
As an example of the utility of this system, our laboratory has
generated mice expressing Cre under control of the
aquaporin-2 (AQP2) promoter; these mice express Cre
selectively within the kidney in principal cells. Breeding
AQP2-Cre mice with mice containing exon 2 of the
endothelin-1 gene flanked by loxP sites ultimately results in
490% loss of collecting-duct endothelin-1 in animals
homozygous for loxP-flanked endothelin-1 gene and hetero-
zygous for the AQP2-Cre transgene.10 These collecting-duct
endothelin-1-knockout mice have marked salt-sensitive
hypertension (systolic blood pressure 40 mm Hg greater than
controls) associated with impaired ability to excrete a Na and
water load. The AQP2-Cre mice have also been used to
demonstrate that selective disruption of peroxisome prolif-
erator-activated receptor-g in collecting duct prevents
thiazolidinedione-induced fluid retention.11,12 The Ksp-
cadherin-Cre mouse that targets thick ascending limb and
distal nephron has been used to inactivate the KIF3A subunit
of kinesin II,19 resulting in cystic kidney disease. Podocyte-
specific knockout of vascular endothelial growth factor-A
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Site-specific 
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Exon(s) in target gene RSRS
RS Exon(s) in target gene RSRS
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Recombined 
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Figure 1 | SSR-mediated recombination of SSR recognition-site (RS)-flanked DNA. When the RSs are in the same orientation, the
intervening DNA is excised. When they are in the opposite orientation, the intervening DNA is inverted.
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using a nephrin-Cre transgenic strategy causes severe
glomerular pathology.27 Several key renal cell-specific Cre-
expressing mice have yet to be constructed, whereas others
have proved challenging. A renin-Cre transgenic mouse
expresses renin primarily in the juxtaglomerular apparatus
and afferent arteriole during adulthood; however, during
development, Cre is expressed in multiple tissues.26 Several
proximal tubule-expressing Cre mice have been constructed;
however, it is unclear whether these target the entire
segment.3–7 Attempts have been made to target mesangial
cells using the megsin promoter, which was identified from a
human mesangial-cell cDNA library;37 however, these have
not been successful (Gawlik and Quaggin,38 and personal
communication with T Miyata, Tokai University, Japan).
Cre can also be used to activate gene expression (Figure 2).
Generally, a promoter with ubiquitous cell activity is used to
drive the expression of a protein of interest; however, the
protein is not synthesized due to insertion of a loxP-flanked
‘STOP’ sequence immediately 30 to the promoter. Cre excises
the STOP sequence, permitting expression of the protein. A
typical application for this strategy has been for labeling cells
that have undergone recombination, using b-galactosidase or
green fluorescent protein as the marker proteins. An elegant
example of this system is its use in fate-mapping studies of
mouse kidney. Iwano et al4 used the g-glutamyl transpepti-
dase (GGT)-Cre transgenic mouse to label adult cortical
tubular epithelial cells. GGT-Cre mice were bred with mice
containing the ubiquitously active ROSA26 promoter-loxP-
STOP-loxP-lacZ. Since GGT becomes active in the kidney
around E14, adult renal epithelium are lacZ-positive. Bone
marrow cells and fibroblasts do not have GGT activity, so
these cells are lacZ-negative. Appearance of lacZ-positive
interstitial fibroblasts in kidneys with ureteral obstruction
demonstrated these cells to have been derived from the
tubular epithelium, and thus indicating that an epithelial-to-
mesenchymal transformation had occurred.
Table 1 | Cre recombinase mouse lines affecting the kidney
Renal cell type Promoter Expression elsewhere Targeted proteins in kidney References
Proximal tubule (largely S3) GGT Uncertain None 3,4
Proximal tubule (largely S1) SGLT2 No None 5
Proximal tubule PEPCK Hepatocytes VHL tumor suppressor, HIF-1 6,7
Proximal tubulea KAP promoter/AGT
intron
Uncertain None 8
Thick ascending limb THP No None 9
Collecting duct—principal cell AQP-2 Testes, vas deferens ET-1, ETA, and B receptors,
PPARg, MC receptor
10–15
Collecting duct—intercalated cellb B1 subunit of vacuolar
proton ATPase
Epididymis, lung None 16
Collecting duct (not connecting segment) Hox-B7 Ureter, spinal cord, dorsal root
ganglia
a-ENaC, AQP-2 17,18
Thick ascending limb and distal nephron Ksp-cadherin No Kinesin-II, others 19–21
Renal tubule and glomeruli Pax-8 Inner ear, brain, thyroid Glucosylceramide synthase 22,23
Renal tubule and glomeruli Pax-2 Inner ear, brain None 24
Renal tubule, not segment specific 11-b-HSD 2 Colon, brain, lung, heart, etc. None 25
JGA and afferent arteriole Renin Adrenal gland, testis, etc. Gs-a
26
Podocyte Nephrin Brain (low) VEGF-A 27
Podocyte Podocin None None 28,29
Interstitial cellc Tenascin-C Mesenchyme during
development and healing
None 30
Kidney (not specific) Apo E Unreported, but likely widely
expressed
Megalin 31
Kidney (not specific) MMTV-LTR Unreported, but likely widely
expressed
Polycystin-1 32
Kidney (not specific) CYP450 1A Unreported, but likely widely
expressed
APC tumor suppressor 33
Kidney (not specific) BMP 7 Unreported, but likely widely
expressed
Smad4 34
Kidney (not specific) Osr-2 E10 mesonephros, palate, limb
buds
None 35
Kidney (not specific) CMV-enhanced b-actin Ubiquitous PAX2 activation 36
AGT, angiotensinogen; APC, Adenomatous polyposis coli; Apo, apolipoprotein; AQP, aquaporin; BMP, bone morphogenic protein; CMV, cytomegalovirus; CY, cytochrome;
ENaC, epithelial Na channel; ET, endothelin; GGT, g-glutamyl transpeptidase; HIF, hypoxia-inducible factor; HSD, hydroxysteroid dehydrogenase; KAP, kidney androgen
protein; MC, mineralocorticoid; MMTV LTR, mouse mammary virus long terminal repeat; Osr, Odd-skipped related; PEPCK, phosphoenolpyruvate carboxykinase; SGLT,
Na-glucose co-transporter; THP, Tamm Horsfall protein; VEGF, vascular endothelial growth factor; VHL, Von Hippel–Lindau.
The table provides data on mouse lines expressing Cre exclusively or primarily within the kidney. A few mouse lines are mentioned, which were not designed to be relatively
or completely renal specific, but have been used to study a renal phenotype. Several other Cre mouse lines exist which have a wide tissue pattern of expression, including
kidney, but these are not discussed herein.
aIn development (personal communication with Dr Curt Sigmund, University of Iowa).
bIn development (personal communication with Dr Raoul Nelson, University of Utah).
cIn development (personal communication with Dr Chaun-Ming Hao, Vanderbilt).
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Several considerations and potential limitations exist with
the Cre/lox system. First, the site of integration of the
promoter-Cre transgene can affect Cre expression, just as any
randomly integrated transgene is subject to so-called
‘positional’ effects. Consequently, many founder lines may
need to be screened for optimal cell-specific Cre activity. Such
positional effects may be avoided by use of BAC or PAC
(bacterial or P1 artificial chromosomes, respectively) trans-
genes due to the large size of these constructs as well as their
containing the entire promoter of interest (see review Bianco
et al.39). Cre may also be inserted downstream of an
endogenous promoter (knock-in) using homologous recom-
bination in ES cells, but this can be substantially more time-
consuming and costly. A second consideration is that Cre
recombinase activity against loxP-flanked alleles varies,
perhaps due to degree of DNA tertiary structure or other
factors. Thus, measures of Cre activity using a reporter
mouse (typically one that expresses b-galactosidase or a
fluorescent protein upon recombination) do not necessarily
reflect activity against other target alleles. A method to
confirm the degree of recombination is to link a reporter
gene with the loxP-flanked target DNA segment so that
recombination activates the reporter; published methods
have met with varying degrees of success in vivo. A potentially
attractive way to accomplish this is to use the so-called
‘FLEX’ system in which Cre causes irreversible inversion of
target DNA in such a manner that the target allele is
inactivated whereas the reporter is activated.40 Despite these
reporter systems, it is still essential to confirm the degree of
knockout of the target allele. Third, it is important to use the
right controls. Ideally, these consist of wild-type mice of the
same strain, mice with loxP-flanked alleles without the Cre
transgene, and mice with the Cre transgene without the loxP-
flanked alleles. The latter control may be important, since
pseudo- (or cryptic) loxP sites exist with a frequency of about
1.2 Mb1 in the mammalian genome.1 The sequence of these
sites may differ from that of loxP, but they are recognized by
Cre, albeit with substantially lower affinity than for loxP. Cre-
mediated recombination at these pseudo-loxP sites may result
in cell injury or undesired functional consequences.41–43
Fourth, promoters confer varying degrees and cell specificity
of Cre expression. In some instances, it is desirable to target
only one cell type in the kidney, and so certain promoters,
such as Ksp-cadherin or HoxB7, would not be candidates.
Other promoters may confer Cre expression in only a subset
of target cells. For example, GGT-Cre is largely active in the
S3, but not S1, segment of the proximal tubule, whereas Ksp-
cadherin gives highly variegated Cre expression in the thick
ascending limb and distal nephron. Such lack of compre-
hensive target allele recombination may not yield a demon-
strable phenotype. However, in cases where complete
knockout is undesirable (perhaps in a cystic kidney disease
model or targeting a gene essential for cell survival),
incomplete Cre expression may be advantageous. Fifth, the
timing of recombination must be considered. Promoters that
are purportedly cell-specific may be active during embryo-
genesis in unforeseen locations, whereas Cre activity even in
the target cell type may cause problems if it occurs during
development. Temporally regulated systems have been
developed to address this issue; these are discussed later in
this review. Sixth, the region of the target gene to be flanked
by loxP sites must be carefully selected, otherwise truncated
or mutated proteins with biologic activity may be synthe-
sized. Finally, mice ultimately containing targeted gene
disruptions may have phenotypes of uncertain significance.
For example, if no unique phenotype is obtained, does this
reflect the biologic insignificance of the targeted gene or
potentially complex compensatory mechanisms?
The Flp/FRT system
The Flp/FRT recombination system is essentially the eukar-
yotic homologue of the Cre/loxP system.44 Flp, a 423-amino-
acid monomeric peptide encoded within the 2-mm plasmid
of Saccharomyces cerevisiae, is very similar to Cre in that it
requires no cofactors, uses a phosphotyrosine intermediate
for energy, and is relatively stable. FRT is also very similar to
loxP in that it is composed of three 13-bp repeats
surrounding an 8-bp asymmetric spacer region. Despite
similar mechanisms of action and DNA-recognition sites, the
Cre/loxP and Flp/FRT systems do not exhibit significant
cross-reactivity.45 Flp is less stable than Cre at 37 1C; however,
a thermostable version, Flpe, has been used for transgenic
Stop Gene of interest No gene expressionPromoter Iox Iox
Gene of interest Gene expressionPromoter Iox
Cre recombinase 
Figure 2 | Cre-mediated gene activation. A loxP (lox)-flanked STOP sequence is inserted between the promoter and the gene of interest,
preventing transcription. Cre excises the STOP sequence, permitting promoter activation of the gene of interest.
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applications. Despite this improvement, Flpe still has low
recombination efficiency (percent of cells undergoing re-
combination). Recently, a mouse codon-optimized Flp
(FLPo) has been constructed with recombination efficiency,
as tested in ES cells, similar to Cre.46 It remains to be seen
whether FLPo is as effective as Cre in mice. The Flp/FRT
system has been shown to cause site-specific DNA recombi-
nation in transgenic mice.47 However, there are no reported
studies employing Flp/FRT to achieve kidney-specific gene
expression or knockout.
Other recombinase systems
Streptomyces lividans phage-derived FC31 mediates recom-
bination between 25 bp attB and 240 bp attP DNA sites.48
Unlike Cre- or Flp-mediated recombination, FC31 results in
the formation of irreversible hybrid attL or attR sites. Initial
studies with FC31 revealed relatively low recombinase
activity in mammalian cells; however, a mouse codon
optimized FC31 (FC31o) has recently been reported to
exert comparable recombination as compared with Cre in ES
cells.46 An interesting feature of FC31 is its recognition of
pseudo-attP sites within the mammalian genome. An
electroporated dystrophin DNA has been demonstrated to
integrate into mouse liver in vivo after injection of a plasmid
encoding FC31, presumably at pseudo-attP sites.49 Using a
similar strategy, FC31 mediated integration of Factor IX into
introduced attP sites in mouse liver.50 This system has not,
however, been reported in transgenic mice; several problems
first need to be addressed. Amongst these is the concern over
FC31 mediating recombination at pseudo-attP sites as well
as between engineered attB and attP sites (unwanted
chromosomal translocations and deletions have been re-
ported). Finally, other recombination systems have been
reported to work in cultured mammalian cells, but with
unproven utility in mice; these include b-recombinase/six
and Dre/rox (similar to Cre).1
TEMPORAL REGULATION OF GENE EXPRESSION
A number of methodologies have been described to achieve
temporally regulated gene expression in mice, including
systems based on the tetracycline transactivator/transrepres-
sor, metallothionein promoter induction by heavy metals,51
polycyclic aromatic hydrocarbon activation of the cyto-
chrome P450 1A1 promoter,52 isopropyl-b-D-thiogalacto-
sidase induction of the b-actin promoter-synlacI repressor,53
interferon induction of the Mx1 promoter,54,55 and hormone
(ecdysone, progesterone or estrogen) receptor-based strate-
gies.56–58 Most of these systems have had limited use in mice
due to a variety of challenges. One of the most common
challenges is transgene activation without inducer being
present. This is typically due to transgene activation by an
endogenous substance. Other challenges include poor
transgene induction and/or inducer toxicity. The two
induction systems that have been used primarily for renal
studies employ doxycycline or tamoxifen as conditional
regulators (Table 2); these will be reviewed here.
The tetracycline system
The tetracycline system uses the bacterial tet resistance
operon to reversibly switch gene expression on and off
(Figure 3). The original system was based on constitutive
expression of a tTA, a fusion protein containing the DNA-
binding domain TetR and the herpes simplex virus VP16
transactivator protein.65 Expression of tTA is controlled by a
promoter that can be used to confer cell specificity. tTA binds
to and activates a promoter with minimal basal activity that
contains several tet-operator (tetO) sites coupled to a
truncated cytomegalovirus (CMV) promoter. The tetO-
minimal CMV promoter is placed 50 to the gene whose
expression is being regulated. Tetracycline (or doxycycline)
binds tTA and prevents its binding to tetO, thereby turning
off gene activation. This is referred to as the tet-off system. A
variant of this system, termed ‘rtTA’, contains a mutated TetR,
Table 2 | Inducible Cre recombinase mouse systems affecting the kidney
Renal cell type Promoter and regulator Expression elsewhere
Targeted proteins in
kidney References
Proximal tubule (S3 only) GGT CreERT2/tamoxifen Possibly testes and
ovaries (integrated in X
chromosome)
None 3
Thick ascending limb and
distal nephron
Ksp-cadherin CreERT2/tamoxifen No Polycystin-1 20,59
Renal tubule and glomeruli Pax-8 rtTA/doxycycline Glomeruli, inner ear,
brain, thyroid
Glucosylceramide
synthase
22
Podocyte Podocin rtTA/doxycycline None None 60
Kidney (not specific) Keratin-18 CreERT2/tamoxifen Epithelia throughout
body
None 61
Kidney (not specific) CMV-enhanced b-actin CreERTM/tamoxifen Ubiquitous AQP-2 62
Kidney (not specific) CMV-enhanced b-actin MerCreMer/
tamoxifen
Ubiquitous None 63
Kidney (not specific) Mx1 interferon Ubiquitous EP4 54,55
Kidney (cap mesenchyme) Cited1 CreERT2/tamoxifen Uncertain Fate mapping 64
AQP, aquaporin; EP4, prostaglandin receptor EP4; GGT, g-glutamyl transpeptidase.
The table provides data on mouse lines conditionally expressing Cre exclusively or primarily within the kidney.
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where binding of rtTA to tetO and gene activation only
occurs in the presence of doxycycline.66 This is called the tet-
on system. In general, the tet-on system is preferred since it
avoids the need for long-term and potentially toxic antibiotic
administration. However, the tet-on system has had problems
with unwanted gene activation due to rtTA binding tetO in
the absence of doxycycline (albeit at a low level), as well as
modest intrinsic activity of the minimal promoter. Modified
versions of rtTA and the minimal promoter have been made,
which confer tighter control of gene expression (see review
Sun et al.67). Another modification involves inclusion of rtTA
with a tet suppressor; the latter constitutively inhibits gene
activation, whereby doxycycline prevents the binding of a tet
suppressor-containing rtTA to tetO.68 While these more
stringent systems hold promise, it remains to be seen whether
they are reliable in transgenic mice. In addition, the need for
at least two, and sometimes three, DNA constructs to drive
Cre expression complicates the breeding scenario. Single
constructs containing all of the desired elements have been
made;67 however, their effectiveness in vivo has not been well
ascertained.
The tet-on system, employing the podocin promoter to
drive rtTA, has been used to temporally regulate podocyte-
specific Cre expression.60 A preliminary report described
usage of the Pax8 promoter coupled to rtTA to control Cre
expression throughout the nephron and to very effectively
knockout glucosylceramide synthase.22 These examples
involve tetracycline-regulated Cre expression; however, con-
ceivably any gene could be regulated, either induced or
knocked out. A key feature of the tet-regulated Cre systems,
as for any temporally regulated strategy, is that fate or lineage
mapping is facilitated. That is, genes can be targeted at
specific points in development, often by activation of a
marker protein (as discussed earlier), such that their fate, as
well as the fate of cells derived from them, can be determined.
Estrogen-based systems
Several steroid hormone-based systems have been used to
achieve gene regulation in mice. The insect steroid, ecdysone,
as well as progesterone or RU486, can induce gene expression
in mice; however, these have had limited utility, in part due
to concerns over leakiness and inducibility. Estrogen
receptor-based systems have now evolved as the major means
of achieving temporal control of gene, and particularly Cre,
expression in mice. The basic principal involves fusion of the
estrogen-binding domain of the estrogen receptor with a
heterologous protein (for example, Cre) (Figure 4). Synthesis
of the fusion protein is controlled by the promoter of interest,
either conferring generalized or cell-specific expression. The
fusion protein is confined to the cytoplasm; however, in the
Promoter TetR VP16
Tet-off system
Gene of interesttet07 CMV*
tTA
Gene of interest
tTA
tet07 CMV*
Doxycycline
Expression No expression
Promoter rTetR VP16
Tet-on system
Gene of interesttet07 CMV*
rtTA
Gene of interest
rtTA
tet07 CMV*
Expression No expression
Doxycycline
Figure 3 | Doxycycline-regulated gene expression. In the tet-off system, the chimeric tetracycline transactivator protein (tTA)
consists of the TetR domain that recognizes tetO fused to the VP16 transactivating domain of herpes simplex virus. tTA binds to seven
tetO domains (tetO7) connected to a minimally active CMV promoter (CMV*), resulting in gene activation. Doxycycline binds tTA and
prevents gene activation. In the tet-on system, TetR is mutated to rTetR, which must have doxycycline present in order to bind to tetO7
and activate gene expression.
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presence of estrogen, translocation to the nucleus occurs. In
the case of Cre, this would permit Cre access to its DNA
targets. Initial attempts at developing this system led to the
development of CreER; however, this strategy was proble-
matic due to endogenous estrogen binding.69 The estrogen
ligand-binding domain was then mutated so that is was
activated by 4-OH-tamoxifen (OHT), but not by estradiol
(G521R resulting in CreERT or G525R resulting in
CreERTM).69 However, these constructs required concentra-
tions of OHT that sometimes caused cell toxicity. This
problem was reduced by development of a triple mutation
involving G525R/M543A/L544A (CreERT2) that increased
OHT affinity 10-fold;70 this is the most commonly used
CreER in mouse transgenic studies. Other CreER constructs
have been devised; MerCreMer is a double fusion of Cre with
two ERTM domains that was created to reduce background
activity of CreERTM.71 In general, current CreER systems
(particularly CreERT2) have modest leakiness and good
inducibility. However, even mild leakiness can sometimes
create problems (such as activation of a tumor-inducer gene);
various strategies to resolve this, such as light regulation of a
photo-caged CreER, have been described but not yet
employed extensively.1 Another consideration is that OHT
sensitivity can vary widely, and so it is necessary to determine
the dosage, route, and frequency of OHT for each applica-
tion. As discussed earlier, use of reporter mice expressing
markers upon recombination assists in this process, but it is
often important to determine the degree of recombination of
the targeted allele. In some cases, complete target gene
recombination is not necessary, such as in the induction of
renal cyst formation, where only a small number of cells may
be need to be affected for cyst formation. In other cases, such
as while evaluating the effect of an ion transporter’s absence,
near-complete knockout of the target gene may be necessary
in order to observe a phenotype.
CreER-regulated gene expression has been achieved in the
kidney (Table 2). This includes use of renal-specific
promoters driving CreER expression, including in the S3
segment of the proximal tubule3 or in the thick ascending
limb and distal nephron.20,59 In addition, regulation of renal
genes (for example, aquaporin-262) using CreER has been
accomplished using promoters which affect multiple tissues,
including promoters for keratin-18, CMV-enhanced b-actin,
and Cited1.61,62,64 In general, renal-specific promoters are
preferable; however, if the target gene is solely expressed in
the kidney, then ubiquitous promoters driving CreER are a
reasonable approach.
RNA INTERFERENCE
RNA interference is a powerful tool for regulating gene
expression. In invertebrates, administration of long double-
stranded RNA results in their cleavage into short (23–25 bp)
interfering RNAs (siRNAs) by the enzyme Dicer.72 The
siRNA antisense strand binds to complementary mRNA in
the presence of the multi-protein RNA-induced silencing
complex. The RNA-induced silencing complex then cleaves
the mRNA, which is subsequently degraded. In mammalian
cells, long double-stranded RNA induces a toxic interferon-
mediated response; however, short double-stranded RNA
(o30 bp) elicit RNA interference without toxicity.73 In the
kidney, venous injection of siRNA targeting Fas,74 comple-
ment 3,75 or caspase 376 ameliorated ischemia–reperfusion
injury. Ureteral injection of siRNA complementary to heat-
shock protein-47 decreased tubulointerstitial fibrosis asso-
ciated with ureteral obstruction.77 Electroporation of siRNA
against transforming growth factor-b1 mRNA reduced
mesangial matrix expansion in experimental glomerulone-
phritis in the rat.78 Despite these reports, in vivo adminis-
tration of siRNA remains problematic. The siRNA are
difficult to deliver throughout the kidney, whether injected
Promoter Cre LBD ER
CreER CreER
CreER
Exon(s) in target gene Iox
Iox
Iox
Nucleus
Cytoplasm
Tamoxifen
Figure 4 | Tamoxifen-regulated gene expression. Cre recombinase is fused to the ligand-binding domain of the estrogen receptor
(LBD ER). The resulting protein, CreER, is confined to the cytoplasm. In the presence of tamoxifen, CreER is translocated to the nucleus,
where it catalyzes recombination of the target DNA sequences flanked by loxP (lox) sites in the same orientation.
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intrarenally, electroporated, or given via ureter, vein,
peritoneum, or renal artery. In addition, the effect of the
siRNA is transient and the degree of knockdown can vary
widely, requiring large numbers of animals.
RNA interference can also be achieved by transcription of
non-protein coding genes. Mammalian cells synthesize short
RNAs (micro-RNA or miRNA); these are transcribed as long
single-stranded miRNA precursors, which contain self-com-
plementary fold-back structures to form regions of double-
stranded RNA.79 These are then processed by Dicer to miRNA,
which, if complementary to a given mRNA, can cause cleavage
(notably, many miRNAs are not highly complementary to
their target mRNA and do not cause cleavage, but can still
inhibit RNA translation). This strategy of nature has been
reproduced with the development of short-hairpin RNA
(shRNA)80 (Figure 5). These vectors contain a promoter
driving expression of two complementary short RNA
sequences separated by a spacer region. The single-stranded
RNA product binds to itself, forming double-stranded RNA
with an RNA loop attached (stem-loop structure). In the
presence of Dicer, the shRNA is processed into siRNA.
The use of shRNA in transgenic animals is in its relative
infancy. Non-germline-transmittable shRNA can be delivered
to somatic cells through viral mechanisms, particularly using
adenoviruses or adeno-associated viruses (exist episomally)
and lentiviruses (incorporate into host chromosome).81 Such
a strategy was employed when adeno-associated virus
containing mineralocorticoid-receptor shRNA was adminis-
tered intravenously to rats with resultant reduction of
cold-induced hypertension and renal damage.82 Note that
this study used rats; hence, a potential advantage of shRNA
virus delivery is the use of animals larger than mice.81 The
greatest utility of shRNA, however, is the ability to generate
animals with germline transmission of the transgene. This has
been accomplished by either lentiviral infection or pronuclear
injection of one-cell embryos, or by targeting ES cells.83
Several considerations are involved while obtaining effective
in vivo RNA silencing using shRNA. First, the siRNA derived
from the shRNA must have the desired knockdown efficiency.
To help assess this, one can screen ES clones for knockdown
efficacy; however, this is time-consuming and does not
guarantee in vivo success. The development of second-
generation shRNA libraries covering the mouse genome,
using shRNA sequences placed on the natural miRNA
background (shRNA-mir), has substantially improved shRNA
efficiency.84 Second, the promoter must confer adequate
shRNA expression. RNA polymerase III promoters, including
U6 and H1, have been favored due to their clear initiation and
termination sites, and effectiveness in mice (particularly
U6).85 Pol II promoters, which modify the 50 and 30 RNA
sequence, are much stronger than RNA polymerase III and
have been used to drive shRNA-mir expression.86 Third, it
would be ideal to achieve conditional regulation of shRNA. It
is possible that tissue-specific promoters could be used to
directly control shRNA expression; however, this has not been
reported. The Cre/lox system has been employed to control
shRNA expression in vivo. LoxP-flanked STOP sequences have
been inserted into different locations within the shRNA
vector, including the loop or the U6 promoter; the stop
sequence prevents shRNA formation.87,88 In the presence of
Cre, the stop sequence is excised and active shRNA is formed.
This approach is clearly adaptable to the use of renal-specific
Cre transgenes. Further control could be obtained using
systems that confer temporal regulation, either with Cre or
without it (the latter would be an advantage in that, unlike
with Cre, gene knockdown would reversible). Tetracycline-
regulated systems controlling shRNA expression have been
described,89,90 although their feasibility in mice has not been
reported. One of these systems, termed potent RNAi using
shRNA-mir expression or pPRIME, potentially allows control
of any shRNA-mir using tet-on or tet-off strategies.89 In the
tet-on construct, the U6 promoter is replaced with
tet-responsive elements and the minimal CMV promoter,
while a green fluorescent protein reporter is included
downstream to mark cells that have promoter activation.
In summary, shRNA transgenic approaches hold much
promise for rapid, effective, and reversible regulation of gene
expression in mice. An additional advantage of shRNA is that
mice homozygous for the transgene are not needed to obtain
gene knockdown, thereby saving time and reducing breeding
costs. However, most transgenic RNAi studies have involved
acute administration of siRNA; much more work must
be done in order to convincingly demonstrate that transgenic
shRNA procedures, including constitutive, cell-specific,
or inducible approaches, is feasible, effective, and reliable
in vivo.
U6  Promoter Sense Loop Antisense
shRNA
siRNA
Dicer
RISC
Target mRNA inactivation
Figure 5 | RNA interference in vivo. Typically, the U6 RNA
polymerase promoter is used to drive the expression of DNA
encoding an RNA containing two complementary 21–23 bp
regions separated by a short loop sequence (shRNA). In the
presence of Dicer, the loop is cleaved, thereby generating siRNA.
siRNA combines with the RNA-induced silencing complex and
acts as a template for inhibition of the complementary mRNA
target.
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ZINC-FINGER NUCLEASES
Zinc-finger nucleases are a relatively recently described
potential addition to the armamentarium of gene-targeting
tools.91 These consist of modular B30-amino-acid zinc-
finger motifs that can be engineered to bind specific DNA
triplets. When linked in tandem and attached to the
endonuclease domain of Fok1, which induces a double-
stranded DNA break, a zinc-finger nuclease is created that
can bind to, and cleave at, specific DNA sites. Zinc-finger
nucleases have been used to insert long DNA sequences into a
specific DNA location in human cells.92 While use of zinc-
finger nucleases in gene targeting is largely undergoing
development, with issues of cell toxicity and site specificity in
need of resolution, this technique has the potential to permit
not only more efficient gene targeting in ES cells, but also to
facilitate insertion of genes into specific sites in vivo.
CONCLUSION
Advances in gene targeting in the mouse have greatly
enhanced understanding of the physiological and pathophy-
siological role of specific gene products in the kidney.
Conditionally regulated transgenic mice employing renal cell-
specific promoters and Cre recombinase are now powerful
tools for investigating renal function in health and disease.
The use of temporally regulated gene expression, particularly
using doxycycline- and tamoxifen-inducible systems, is likely
to have substantial added benefit. Although still largely
unproven, it is probable that RNAi-based systems will be
developed that have the advantage of rapid, reversible, and
inducible regulation of renal gene expression. Additional new
tools for gene targeting are being developed that may
markedly simplify generation of transgenic animals.
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